Ira Shafran

Ira Shafran

Auto-generated profile, based on publicly available information

Ira Shafran

Shafran Gastroenterology Center, Winter Park, Florida, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Digestive and Liver Disease
Verified
Journal Article
Closed access
ISI. Shafran
I. Shafran
LKL. Kugler
L. Kugler
FKF.A.X. Kl-Zaatari
F.A.X. Kl-Zaatari
SNS.A. Naser
S.A. Naser
JSJ. Sandoval
J. Sandoval

20 March 2009 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
CRClaudia Pena Rossi
Claudia Pena Rossi
SHStephen B Hanauer
Stephen B Hanauer
RTRatko Tomasevic
Ratko Tomasevic
JHJohn O Hunter
John O Hunter
ISIra Shafran
Ira Shafran
HGHans Graffner
Hans Graffner
Crohn's disease (CD) and multiple sclerosis (MS) share common pathogenic processes. Interferon (IFN) beta-1a is effective and generally well tolerated in patients with MS and has been shown to down-regulate the expression of interleukin-12, a cytokine that is thought to be involved in mucosal degeneration in CD. IFN beta-1a therefore offers promise as a treatment for CD.